Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.01, read 2026-11-05
Ethical passes the values gate
Price88.24 USD
Fair value110.00
Ethical score83.2/100
Value readUndervaluedas of 4 Nov 2026
Our investment reviews on this name
2026-10-30Read Accumulation86.44+2.1% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown84.97+3.8% to today Accumulation gives way to Markdown with volume flow in agreement
2026-08-01Read Accumulation85.17+3.6% to today ✓Distribution gives way to Accumulation after a 10% rise in 4 weeks
2026-07-02Read Distribution77.45+13.9% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Henry Schein holds its Distribution at $88.24. Consolidating, no directional conviction, held for 228 days.
As held on the ledger · 2026-11-04
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 228 days
Price at the screen
$88.24
Valuation
24.05 trailing · 13.77 forward price to earnings
Values screen
PASS· score 83.2
Beta
0.86
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.64%
Below 33%
Interest-bearing debt is just 30.6% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.55%
Below 33%
Cash held in interest-bearing accounts and securities is 1.6% of assets, under the one-third limit.
Pass
Receivables
16.11%
Below 49%
Money owed to the company is 16.1% of assets, under the 49% limit.
Pass
Revenue purity
0.25%
Below 5%
Only 0.3% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Henry Schein clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HSIC's ethical verdict changes
Today HSIC passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 4 Nov 2026: it trades at roughly a 20% discount to our $110.00 fair value, weak competitive moat, 6.70% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. A 19.8% discount to the base estimate.
Where our models see it going: fair-value estimate $110.00, with a range of $98.84 to $164.73, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Dental Supplier Priced Below Its Steady Worth
Picture a dentist in Ohio ordering gloves and equipment for the week ahead. Henry Schein moves those products from warehouse to chair side across dozens of countries. At 14.9 times forward earnings and a 14 percent discount to our fair value the shares look reasonable for a business growing revenue 6 percent a year while clearing the ethical screen.
The weak moat and 9 percent return on equity keep the story grounded. Thin 3 percent profit margins leave little room for error if larger rivals or direct-to-practitioner models gain ground. Currency moves and reimbursement pressure in healthcare can also bite harder than the current multiple suggests.
Consensus targets sit near the present price, so the margin of safety rests on execution rather than excitement. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HSIC trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Accumulation$86.62+2.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$84.88+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$84.88+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$84.88-1.8%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Markdown$84.96+1.2%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$83.97+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$83.97+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$83.970.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87.
2026-10-14Markdown$84.01-1.1%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 11%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (14 analysts) rates it none, with a mean price target of $87.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
